Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors
Hematology / Oncology Clinics of North America , Volume 30 - Issue 1 p. 179- 191
Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.
|Carcinoid, Neuroendocrine tumor, PRRT, Radionuclide therapy, Treatment|
|Hematology / Oncology Clinics of North America|
|Organisation||Department of Nuclear Medicine|
Kwekkeboom, D, & Krenning, E.P. (2016). Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematology / Oncology Clinics of North America (Vol. 30, pp. 179–191). doi:10.1016/j.hoc.2015.09.009